The global liquid biopsy market, poised for significant growth, benefits from increased demand for non-invasive cancer ...

The rise in chronic diseases, especially cancer, fuels demand for early, non-invasive diagnostics offered by EV-based liquid biopsies. Key growth opportunities lie in the development of sensitive ...

The market for minimally invasive biopsy techniques is driven by growing cancer prevalence, patient preference for less ...

Early-stage gastric cancer can be assessed more accurately using a new liquid biopsy tool that predicts lymph node metastasis ...

This growth is primarily driven by the rising global cancer incidence, increasing preference for non-invasive diagnostic ...

Early-stage gastric cancer can be assessed more accurately using a new liquid biopsy tool that predicts lymph node metastasis ...

The Liquid Biopsy market is projected to grow robustly from US$ 4.29 Billion in 2024 to US$ 15.46 Billion by 2033, driven by ...

CUPid is what is known as a 'liquid biopsy' - blood tests that look for tiny fragments of cancer DNA in the blood. Developed at The Christie and the University of Manchester, this technique is so ...

Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation November 26, 2025 9:00 ...

Blood tests that promise to spot cancer before symptoms appear are racing toward clinics, pitched as a simple vial of blood ...

The prospect of diagnosing cancer through painless methods—such as a simple AI-assisted blood or urine test that detects tiny particles known as exosomes—is becoming increasingly realistic. Scientists ...

Grail Inc. is downgraded from Speculative Buy to Hold after a rapid share price surge from $55 to $100. Click here to read my ...